1FW/1620

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Scott D. Edmondson, et ap

Serial No. 10/560,771

Filed: December 13, 2005

For: CYCLOHEXYLGLYCINE DERIVATIVES AS

DIPEPTIDYL INHIBITORS FOR THE TREATMENT OR

PREVENTION OF DIABETES

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Art Unit: To Be Assigned

Examiner: <u>To Be Assigned</u>

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- 3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
- 4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

y Leux Bross

__ Date 3/9/2006

MAR 1 9 2006 W

INFORMATION DISCLOSURE STATEMENT

5. Pursuand A. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

	RELATED A	PPLICATION
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE
10/540,283	June 20, 2005	21304YP
10/537,476	June 3, 2005	21288YP
10/530,215	April 4, 2005	21239YP
10/542,694	July 19, 2005	21329YP
10/556,805	November 14, 2005	21404P
10/558,931	November 30, 2005	21431P

If this is inconvenient, additional copies will be submitted upon request.

(6. In accordance with 37 C.F.R. 1.97, (check one)	
\checkmark	the attached information is filed within three months of the filing da	ite of the captioned case.
	the attached information is filed more than three months after the f Office Action on the merits.	filing date but prior to the mailing of a first
	the attached information is filed before the mailing of a first Office examination under §1.114.	action after the filing of a request for continued
	the attached information is being filed more than three months after Office Action on the merits, but before the mailing date of a Final Action otherwise closes prosecution in the application. The enclosed authorized Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).	Action, Notice of Allowance, or an action that horization is therefore given to charge Deposit
	each item of information contained in this Information Disclosure S from a foreign patent office in a counterpart foreign application not Statement.	
	each item of information contained in the information disclosure st a foreign patent office in a counterpart application and this commu- designated in §1.56(c) more than thirty days prior to the filing of the	inication was not received by any individual
	no item of information contained in this Information Disclosure State foreign patent office in a counterpart foreign application, and, to the after making reasonable inquiry, was known to any individual designanths prior to the filing of this Statement.	e knowledge of the person signing the certification
		Respectfully submitted,
		Chippe & Owello
		By: Philippe L. Durette
		Attorney For Applicant(s)
		Reg. No. <u>35,125</u>
		MERCK & CO., INC. Patent Dept., RY60-30
		P.O. Box 2000
		Rahway, N.J. 07065-0907
		(732)594- <u>4568</u>
		Date: March 9, 2006

Substitute for form 1449A/PTO		Patent and Trademark Office: U.S DEPARTMENT OF COMMERCE COMPLETE IF KNOWN
INFORMATION DISCLOSURE	Application Number	10/560,771
CONTA FEMMENT DV A DDI ICANIT	Filing Date	December 13, 2005
OSTATEMENT BY APPLICANT	First Named Inventor	Scott D. Edmondson, et al.
MAR 1 3 2006 (use as mony sheets as necessary)	Group Art Unit	
\ 1 \ 3 \ .6\\	Examiner Name	
Sheet RADEMAPH 1 of 5	Attorney Docket Number	21443P

			U.S. PA	ATENT DOCUMENTS	· - · · ·
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
/GS/	1	6,699,871 B2		Edmondson et al.	03/02/2004
1	2	6,011,155		Villhauer	01/04/2000
1000	3	6,166,063		Villhauer	12/26/2000
2000000	4	5,939,560		Jenkins et al.	08/17/1999
odasso	5	6,303,661 B1		Demuth et al.	10/16/2001
	4	6,432,969 B1		Villhauer	08/13/2002
V	7	4,386,090		Moinet et al	05/31/1983
					_
		*			

	FOREIGN PATENT DOCUMENTS								
Initials* N		G:		Foreign Patent Documen	t	N. C.B.	Date of Publication of		
		Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY		
/(3S/ 	8	PCT	WO 03/082817 A2		MERCK & CO., INC.	10/09/2003		
yaddadi		9	PCT	WO 03/000180 A2		MERCK & CO., INC.	01/03/2003		
		10	РСТ	WO 03/000181 A2		MERCK & CO., INC.	01/03/2003		
		11	PCT	WO 03/000181 A3		MERCK & CO., INC.	01/03/2003		
		12	PCT	WO 02/076450 A1		MERCK & CO., INC.	10/03/2002		
	0000000	13	PCT	WO 2004/007468 A1		MERCK & CO., INC.	01/22/2004		
	00000	14	PCT	WO 2004/032836 A2		MERCK & CO., INC.	04/22/2004		
	opodonia	15	PCT	WO 2004/050022 A2		MERCK & CO., INC.	06/17/2004		
-	9	16	PCT	WO 2004/058266 A1		MERCK & CO., INC.	07/15/2004		
	V	17	PCT	WO 2004/064778 A2		MERCK & CO., INC.	08/05/2004		

Examiner Signature Date Considered

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO		COMPLETE IF KNOWN
INFORMATION DISCLOSURE	Application Number	10/560,771
APAFEMENT DV ADDLICANT	Filing Date	December 13, 2005
STATEMENT BY APPLICANT	First Named Inventor	Scott D. Edmondson, et al.
MAR 1 3 2006 w (use as merry sheets as necessary)	Group Art Unit	
(use as menty sheets as necessary)	Examiner Name	
Sheet HADENIA 2 of 5	Attorney Docket Number	21443P

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.	U.S. Patent Docume		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY		

				FOREIG	N PATEN	Γ DOCUMENTS	
Initia		Cite No.	Office	Foreign Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
7G	is/	18	PCT	WO 2004/069162 A2		MERCK & CO., INC.	08/19/2004
200000		19	PCT	WO 02/02560 A2		NOVO NORDISK A/S	01/10/2002
		20	PCT	WO 01/96295 A2		NOVARTIS AG	12/20/2001
		21	PCT	WO 01/96295 A3		NOVARTIS AG	12/20/2001
		22	PCT	WO 01/34594 A1		Guilford Pharmaceuticals, Inc.	05/17/2001
	odobbo	23	PCT	WO 00/34241		NOVARTIS AG	06/15/2000
	2000000	24	PCT	WO 98/19998 A2		NOVARTIS AG	05/14/1998
	000000	25	PCT	WO 98/19998 A3		NOVARTIS AG	05/14/1998
		26	PCT	WO 97/40832		Hansknoll-Institut Fur Naturstoff-Forschung E.V.	11/06/1997
M	V	27	PCT	WO 03/000180 A3		MERCK & CO., INC.	01/03/2003

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

					Patent and Trademark Office: U.S DEPARTMENT OF COMMERCE	
	Substitute for form 1449A/PTO				COMPLETE IF KNOWN	1
	INFORMATION	DIS	CLOSURE	Application Number	10/560,771	
/	STATEMENT BY	7 A D	DIICANT	Filing Date	December 13, 2005	
	MAR 1 3 2006 g	АГ	LICANI	First Named Inventor	Scott D. Edmondson, et al.	
١ ١	M-1			Group Art Unit		
	(use as monly sheets	s as n	ecessary)	Examiner Name		
	eet 3	of	5	Attorney Docket Number	21443P	_
311	5	01	3	Attorney Docker Number	214431	,

U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.	U.S. Patent Documen		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY			
-		-						

			FOREI	GN PATEN	T DOCUMENTS	
Examine Initials*	Cite No.	Office	Foreign Patent Documen Number	t Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
/GS/	28	PCT	WO 02/02560	A 3	NOVO NORDISK	01/10/2002
90000	29	PCT	WO 01/42262		AKZO NOBEL N.V.	06/14/2001
000000	30	PCT	WO 2004/043940		MERCK & CO., INC.	05/27/2004
2500000	31	PCT	WO 2004/007468		MERCK & CO., INC.	01/22/2004
0,000	32	PCT	WO 2004/110436		MERCK & CO., INC.	12/23/2004
900005	33	PCT	WO 2004/112701	A2	MERCK & CO., INC.	12/29/2004
googook	34	PCT	WO 2004/112701	A3	MERCK & CO., INC.	12/29/2004
	35	PCT	WO 2005/011581	A2	MERCK & CO., INC.	02/10/2005
\/	36	PCT	WO 2005/044195	A2	MERCK & CO., INC.	05/19/2005
W	37	PCT	WO 2005/002530	A2	SMITHKLINE BEECHAM CORP.	01/09/2003

Examiner	Date
Signature	Considered

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	Patent and Trademark Office: U.S DEPARTMENT OF COM	MMERCE
COMPLETE IF KNOWN		
Application Number	10/560,771	
Filing Date	December 13, 2005	
First Named Inventor	Scott D. Edmondson, et al.	
Group Art Unit		
Examiner Name		
Attorney Docket Number	21443P	
	Application Number Filing Date First Named Inventor Group Art Unit Examiner Name	Application Number 10/560,771 Filing Date December 13, 2005 First Named Inventor Scott D. Edmondson, et al. Group Art Unit Examiner Name

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY		
	-						
_							

			FOREI	GN PATENT	Γ DOCUMENTS	
Examiner Initials*	No.	Office	Foreign Palent Documen Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
/GS/	38	PCT	WO 2005/056003	AI	GRAFFINITY PHARMACEUTICALS AG	06/23/2005
0000000	39	PCT	WO 2005/056013	Al	GRAFFINITY PHARMACEUTICALS AG	06/23/2005
0000000	40	PCT	WO 2005/108382	Al	MERCK & CO., INC.	11/17/2005
00000	41	PCT	WO2005/116029	Al	MERCK & CO., INC.	12/08/2005
V	42	PCT	WO 2005/123685	A1	ASTRAZENECA AB	12/29/2005

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449B/PTO	COMPLETE IF KNOWN		
INFORMATION DISCLOSURE	Application Number	10/560,771	
STATEMENT BY APPLICANT	Filing Date	December 13, 2005	
/	First Named Inventor	Scott D. Edmondson, et al.	
MAR 1 9 2006 E	Group Art Unit		
(use as maio/sheets as necessary)	Examiner Name		
Sheet 5 of 5	Attorney Docket Number	21443P	

		NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.				
/GS/ 43		J. J. Holst, "Treatment of Type 2 Diabetes Mellitus with Agonists of the GLP-1 Receptor or DPP-IV Inhibitors", Expert Opin. Emerg. Drugs, Vol. 9(1) pp. 155-166(2004).				
000000000000000000000000000000000000000	44	C. F. Deacon, et al., "Inhibitors of dipeptidyl peptidase IV: A Novel Approach for the Prevention and Treatment of Type 2 Diabetes?", Expert Opin. Investig. Drugs, Vol. 13(9) pp. 1091-1102(2004).				
300000000000000000000000000000000000000	45	K. Augustyns et al., "Dipeptidyl Peptidase IV Inhibitors as New Therapeutic Agents for the Treatment of Type 2 Diabetes", Expert Opin. Ther. Patents, Vol. 13(4), pp. 499-510(2003).				
	46	Novartis AG: WO0034241, "Novel N-substituted-2-Cyanopyrrolidines as Potent Inhibitors of Dipeptidyl Peptidase IV in the Treatment of Non-Insulin-Dependent Diabetes Mellitus", Exp. Opin. Ther. Patents, Vol. 10(12), pp. 1937-1942 (2000).				
	47	O. J. Orucker, "Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes", Exp. Opin Invest. Drugs, Vol.12, pp. 87-100 (2004).				
***************************************	48	T. P. Vahl & D. A. D'Alessio, "Gut peptides in the treatment of diabetes mellitus" Exp. Opin. Invest. Drugs, Vol. 13, pp. 177-188 (2004).				
	49	L. B. Knudsen, "Glucagon-like peptide-1: The Basis of a New Class of Treatment for Type 2 Diabetes", J. Med. Chem, Vol. 47, pp. 4128-4134 (2004).				
000000	50	A. E. Weber, "Dipeptidyl Peptidase IV Inhibitors for the Treatment of Diabetes", J. Med. Chem, Vol. 47, pp. 4135-4141 (2004).				
8080500000000000	51	J. J. Holst and C. F. Deacon, "Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus", Curr. Opin Pharmacology, Vol. 4, pp. 589-596 (2004).				
000000000000000000000000000000000000000	52	C. F. Deacon, "Perspectives in Diabetes - Therapeutic Strategies Based on Glucagon-Like Peptide 1", Diabetes, Vol. 53, pp. 2181-2189 (2004).				
0000000000000	53	K. Augustyns, et al., "Inhibitors of proline-specific dipeptidyl peptidase: DPP IV inhibitors as a novel approach for the treatment of Type 2 diabetes", Expert Opin. Ther. Patents, Vol. 15(10), pp. 1387-1407 (2005).				
V	54	Hans-Ulrich Demuth, et al., " Type 2 diabetes - Therapy with dipetidyl peptidase IV inhibitors", Biochimica et Biophysica Acta, Vol. 1751, pp., 33-44 (2005).				
*						

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /GS/

		the state of the s	
Examiner Signature	/Golam Shameem/	Date Considered	02/14/2008